Scarica l'app Stockscreener
464.56
1.84%
-8.73
Dopo l'orario di chiusura:
465.34
0.78
+0.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$473.29
Aprire:
$472.67
Volume 24 ore:
671.99K
Relative Volume:
0.62
Capitalizzazione di mercato:
$61.37B
Reddito:
$3.21B
Utile/perdita netta:
$43.57M
Rapporto P/E:
1,931.64
EPS:
0.2405
Flusso di cassa netto:
$221.36M
1 W Prestazione:
+4.37%
1M Prestazione:
+9.70%
6M Prestazione:
+52.16%
1 anno Prestazione:
+82.38%
Intervallo 1D:
$464.56
$477.06
Intervallo di 1 settimana:
$444.43
$479.79
Portata 52W:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flowsPrice Action & Risk Controlled Daily Trade Plans - Newser
What hedge fund activity signals for Alnylam Pharmaceuticals Inc. stock2025 Market Trends & Weekly Watchlist for Hot Stocks - Newser
What dividend safety rating applies to Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 WrapUp & Daily Profit Focused Stock Screening - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock trading at attractive multiplesJuly 2025 Price Swings & Weekly Hot Stock Watchlists - Newser
Alnylam Pharmaceuticals (ALNY): Is the Stock’s Recent Surge Justified by Its Valuation? - simplywall.st
Will Alnylam Pharmaceuticals Inc. stock benefit from commodity pricesPortfolio Performance Report & Stock Market Timing Techniques - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfoliosWeekly Profit Summary & Low Risk High Win Rate Picks - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock prepared for digital transition2025 Price Targets & Low Risk Entry Point Tips - Newser
How Alnylam Pharmaceuticals Inc. stock benefits from tech adoption2025 Technical Overview & Risk Adjusted Buy/Sell Alerts - Newser
Alnylam Pharmaceuticals Announces Changes to Board of Directors - PharmiWeb.com
Alnylam Pharmaceuticals announces changes to board of directors - marketscreener.com
Alnylam announces board changes, appoints Stuart Arbuckle as director By Investing.com - Investing.com India
Quadrature Capital Ltd Trims Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Will Alnylam Pharmaceuticals Inc. (DUL) stock boost dividends furtherJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policies2025 Bull vs Bear & Smart Allocation Stock Reports - Newser
Will Alnylam Pharmaceuticals Inc. (DUL) stock benefit from mergersTrend Reversal & Risk Adjusted Buy/Sell Alerts - Newser
Alnylam Pharma, Atour Lifestyle, MongoDB Among These 10 Stocks Worth Watching - Investor's Business Daily
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga
Options Movement At Alnylam Pharmaceuticals: Yvonne Greenstreet Exercises Worth $1.72M - Benzinga
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumMarket Movement Recap & AI Powered Market Entry Strategies - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock good for wealth creationJuly 2025 Catalysts & High Accuracy Swing Trade Signals - Newser
CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing - Barron's
Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (0HD2.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following Raised Sales Guidance for Vutrisiran - simplywall.st
What's Going On With Alnylam Stock On Friday? - Benzinga
Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterWeekly Earnings Recap & Technical Confirmation Trade Alerts - moha.gov.vn
Alnylam Pharmaceuticals Reports Strong TTR Growth Amid Challenges - MSN
IPO Launch: Why Alnylam Pharmaceuticals Inc. stock could be next big winnerMarket Risk Analysis & High Conviction Buy Zone Alerts - moha.gov.vn
ETFs Investing in Alnylam Pharmaceuticals, Inc Stocks - TradingView
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3 - Seeking Alpha
A Look at Alnylam Pharmaceuticals's Valuation Following Raised Sales Guidance on Vutrisiran Outperformance - simplywall.st
Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3 - MSN
Backdoor AI Beneficiary Yields 8.8%, Trades at 13% Discount - Investing.com
Alnylam’s TTR Franchise Drives Big Revenue Growth And Raises Guidance - Finimize
MoA Mid Cap Growth Fund's Alnylam Pharmaceuticals Inc(ALNY) Holding History - GuruFocus
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After Recent Share Price Pullback - Yahoo Finance
Is Alnylam Pharmaceuticals Stock Justified After 73.9% Surge and Clinical Trial Milestones? - simplywall.st
Small Interfering RNA (siRNA) Therapeutics Market 2025: - openPR.com
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years - Benzinga
Alnylam's ATTR cardiomyopathy drug backed for NHS use - pharmaphorum
NICE Final Draft Guidance backs Alnylam’s Amvuttra - The Pharma Letter
Why Alnylam Pharmaceuticals Inc. (DUL) stock attracts wealthy investorsJuly 2025 Institutional & Expert Approved Trade Ideas - newser.com
Alnylam Pharmaceuticals Faces Weak Start with 6.56% Gap Down Amid Market Concerns - Markets Mojo
UK's drug-cost watchdog recommends Alnylam's heart disease drug - Reuters
UK’s drug-cost watchdog recommends Alnylam’s heart disease drug - The Mighty 790 KFGO
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):